Savara Inc. (SVRA) NASDAQ
5.25
+0.1(+1.94%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
5.25
+0.1(+1.94%)
Currency In USD
Address
Building III
Langhorne, TX 78746
United States of America (the)
Phone
512 614 1848
Website
Sector
Healthcare
Industry
Biotechnology
Employees
59
First IPO Date
April 28, 2017
| Name | Title | Pay | Year Born |
| Matthew Pauls | Chairman & Chief Executive Officer | 975,000 | 1971 |
| David L. Lowrance | Chief Financial & Administrative Officer and Secretary | 665,625 | 1968 |
| Robert Lutz | Chief Operating Officer | 665,625 | 1969 |
| Yasmine Wasfi | Chief Medical Officer | 681,578 | N/A |
| Brian Maurer | Head of Clinical Operations | 0 | N/A |
| Brian Robinson | Executive Vice President of Global Medical Affairs | 0 | N/A |
| Siddharth J. Advant | Executive Vice President of Global Technical Operations | 0 | N/A |
| Charles LaPree | Executive Vice President & Head of Global Regulatory Affairs | 0 | N/A |
| Anne Erickson | Chief Business & Corporate Affairs Officer | 0 | 1972 |
| Kate McCabe | Chief Legal Officer | 0 | 1986 |
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.